All treatment groups in Vertex Pharmaceuticals Inc.’s phase II study of the non-opioid VX-548 showed meaningful reductions in pain from baseline in treating diabetic peripheral neuropathy (DPN), pointing the company toward pivotal phase III studies and prompting analysts to applaud enthusiastically.
Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed Lyrica (pregabalin, Pfizer Inc) in a head-to-head trial in diabetic nerve pain.
New optically active benzodiazepines have been reported in a recent Kyonggi University patent as potentially useful for the treatment of diabetic neuropathy.
Sichuan Haisco Pharmaceutical Co. Ltd. has disclosed AP2-associated protein kinase 1 (AAK1) inhibitors reported to be useful for the treatment of diabetic neuropathy and postherpetic neuralgia.
Neuropathic pain affects about 60% of patients with diabetes. The hepatocyte growth factor (HGF)/MET pathway is known to play a critical role in neurogenesis and nervous system repair; thus, its stimulation may provide neuroprotective effects, as well as reduce pain symptoms.
Medshine Discovery Inc. has disclosed derivatives of a six-membered heteroaromatic urea ring acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of diabetic and hypertensive nephropathy.
Dyansys Inc. obtained its second greenlight from the FDA this month for its Primary Relief device to alleviate pain following caesarean-section birth. The company received 510(k) clearance for its First Relief system for painful diabetic neuropathy on July 18. Both systems stimulate nerves on the outer surface of the ear using a percutaneous electrical nerve stimulator (PENS) system.
Investigators at the National Institute of Biological Sciences in Beijing and China Agricultural University have identified mixed lineage kinase domain-like protein as an important player in diabetic neuropathy.
Nevro Corp.'s spinal cord stimulation system cut diabetic neuropathy pain in half or more in 85% of patients in a study published on April 5 in JAMA Neurology. Patients receiving the stimulation treatment delivered by the Senza system experienced an average reduction in pain of 76% at six months in the largest clinical largest trial to date to evaluate the use of spinal cord stimulation (SCS) in painful diabetic neuropathy (PDN).
